Research announced today is the first of its kind to suggest that anti-amyloid drugs can delay or even stop the progression ...

For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from ...

Treatment with donanemab (Kisunla) raised the risk of amyloid-related imaging abnormalities (ARIA) in people with early ...

And though drugs that have some effect on Alzheimer’s disease, dementia’s most common manifestation, have recently been ...

But in just the past year and a half, two anti-amyloid drugs—lecanemab (Leqembi) and donanemab (Kisunla ... amyloid and tau. At some point, researchers believe, those protein clumps start ...

Diagnosing Alzheimer's disease before people have any symptoms is possible, but brings up concerns when so few treatments are ...

A so-called 'miracle' Alzheimer's drug caused brain bleeds in more than a third of patients, a new study has revealed.

Therefore, safety monitoring is necessary with donanemab ... It is thought to be caused by a build-up of amyloid and tau in the brain, which clump together and from plaques and tangles ...

5 – Role of tau protein Lilly has received praise ... attention will undoubtedly shift to ongoing studies of donanemab and other amyloid therapies in patients with earlier-stage disease and ...

Such tests are increasingly moving beyond their origins in cutting-edge research and into the laboratory and diagnostic ...